|
|
|
|
|
|
|
14.10.26 - 18:33
|
Eurofins Scientific: Director/PDMR Shareholding (Business Wire)
|
|
|
LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1.
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Analytical Bioventures S.C.A (RCS B89265)
23, Val Fleuri, L-1526 Luxembourg
2.
Reason for the notification
a)
Position / status
Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin
b)
Initial notification / amendment
Initial
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Eurofins Scientific S.E.
b)
...
|
|
|
|
|
|
|
|
|
|
|
14.10.26 - 12:13
|
AbbVie Aktie: Mit Zukauf die Pipeline weiter stärken (Aktiencheck)
|
|
|
Paris (www.aktiencheck.de) - AbbVie-Aktienanalyse von BNP Paribas:
Egmond Haidt von BNP Paribas nimmt die Aktie des US-Pharmakonzerns AbbVie Inc. (ISIN: US00287Y1091, WKN: A1J84E, Ticker-Symbol: 4AB, NYSE-Symbol: ABBV) unter die Lupe.
Aktionäre von AbbVie würden gespannt auf den 30. Oktober warten, dann werde der US-Pharmakonzern die 9-Monats-Zahlen vorlegen. [mehr]...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.10.26 - 19:06
|
Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan (Business Wire)
|
|
|
Since July 2026, Medincell has secured €41.8 million in non-dilutive financing, repaid 50% of its European Investment Bank (EIB) loan, and extended its debt maturity profile through September 2031.MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) today announced that it has secured an additional €13.8 million in non-dilutive financing from leading European commercial banks and Bpifrance. This additional financing follows the €28 million in non-dilutive bank financing announced in July 2026, bringing the total amount of non-dilutive financing secured since July 2026 to €41.8 million.
The financing has been secured on market terms and does not include any equity-linked instruments, resulting in no dilution for existing shareholders.
Financial Position Snapshot
€84.8 million in cash and cash equivalents as of March 31, 2026
€41.8 million in non-dilutive financing secured since July 2026, including the financing announced today
€23.2 million repaid to the EIB in July 2026, ...
|
|
|
13.10.26 - 17:48
|
SMAIO Reports First-Half 2026 Results and Sales for the Third Quarter of 2026 (Business Wire)
|
|
|
Half-year sales rose by 3% to €5.1m, driven by implant sales in the United States, which increased by 3% to €3.9m (up 10% to $4.5m, excluding currency effects)
Solid gross margin of 81%
EBITDA of -€0.8m, reflecting increased R&D investments and marketing efforts to expand the network of surgeons
Cash position of €7.0m at June 30, 2026, providing support for the R&D and sales strategy
Revenue for the first 9 months of 2026 rose by 2% to €7.2m, driven by significant diversification of the customer base, reducing reliance on certain long-standing accounts
Expansion of the North American network to support sustained long-term growth driven by the rise of the open platform and the signing of new accounts
Webconference in French today at 6 p.m. (CEST):
REGISTER HEREDALLAS & LYON, France--(BUSINESS WIRE)--Regulatory News:
SMAIO (Software, Machines and Adaptive Implants in Orthopaedics – Euronext Growth Paris, ISIN Code: FR0014005I80 / Ticker: ALSMA, eligible for the PEA-PME scheme), a French-American...
|
|
|
13.10.26 - 17:48
|
IMPLANET Reports Revenue of €10.6 Million for the First Nine Months of 2026, up 21% (Business Wire)
|
|
|
Q3 2026 revenue up 18% to €3.44 million
Ninth consecutive quarter of sustained growth
U.S. revenue up 32% in Q3 2026 and 45% over the first nine months of 2026 compared with 2025
BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced medical equipment, today announces its revenue for the third quarter of 2026, ended September 30, 2026, and for the first nine months of 2026.
Ludovic Lastennet, IMPLANET's Chief Executive Officer, stated: “The growth recorded over the first nine months of 2026 confirms the strength of our commercial momentum, as reflected in the 21% increase in revenue at the end of September. We have now achieved our ninth consecutive quarter of sustained growth. This performance has been driven by the continued expansion of our Spine Implants and Medical Equipment businesses, with particularly strong ...
|
|
|
13.10.26 - 13:36
|
Zoetis Appoints Iris Knobloch to its Board of Directors (Business Wire)
|
|
|
Knobloch brings deep expertise in consumer strategy, digital transformation, international leadership, and global board experience to the Zoetis BoardPARSIPPANY, N.J.--(BUSINESS WIRE)--$ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced the appointment of Iris Knobloch to its Board of Directors, effective as of December 1, 2026. With decades of experience across global media and consumer businesses, Ms. Knobloch brings a distinct combination of international leadership, proven public company board experience across financial services, hospitality and media, and deep consumer and digital expertise to the Zoetis Board. She currently serves on the boards of Deezer S.A., Lazard, Inc. and Vail Resorts, Inc., and has built a track record of effective governance across complex, global organizations.
Ms. Knobloch has served as President of the Festival de Cannes, a leading international film festival, since July 2022 and is the first woman to hold the position. From 2021 to July 2022, she served as Chair a...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
